818 related articles for article (PubMed ID: 22250078)
1. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
2. Improved outcome of adult recipients with a high model for end-stage liver disease score and a small-for-size graft.
Yi NJ; Suh KS; Lee HW; Shin WY; Kim J; Kim W; Kim YJ; Yoon JH; Lee HS; Lee KU
Liver Transpl; 2009 May; 15(5):496-503. PubMed ID: 19399732
[TBL] [Abstract][Full Text] [Related]
3. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
[TBL] [Abstract][Full Text] [Related]
4. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
Taniguchi M
Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
[TBL] [Abstract][Full Text] [Related]
5. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
[TBL] [Abstract][Full Text] [Related]
6. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
Berry K; Ioannou GN
Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
[TBL] [Abstract][Full Text] [Related]
9. Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma.
Roma J; Balbi E; Pacheco-Moreira L; Zyngier I; Araujo A; Agoglia L; Steinbruck K; Velaverde LG; Martinho JM
Transplant Proc; 2012 Oct; 44(8):2423-7. PubMed ID: 23026611
[TBL] [Abstract][Full Text] [Related]
10. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
[TBL] [Abstract][Full Text] [Related]
11. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
Ioannou GN; Perkins JD; Carithers RL
Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation for hepatocellular carcinoma: the MELD impact.
Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
14. Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.
Samuel D; Colombo M; El-Serag H; Sobesky R; Heaton N
Liver Transpl; 2011 Oct; 17 Suppl 2():S6-13. PubMed ID: 21858912
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era.
Levi DM; Tzakis AG; Martin P; Nishida S; Island E; Moon J; Selvaggi G; Tekin A; Madrazo BL; Narayanan G; Garcia MT; Feun LG; Tryphonopoulos P; Skartsis N; Livingstone AS
J Am Coll Surg; 2010 May; 210(5):727-34, 735-6. PubMed ID: 20421039
[TBL] [Abstract][Full Text] [Related]
16. The impact of Milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the Hungarian Liver Transplant Program.
Nemes B; Gelley F; Piros L; Zádori G; Görög D; Fehérvári I; Kóbori L; Sárváry E; Nagy P; Kiss A; Doros A
Transplant Proc; 2011 May; 43(4):1272-4. PubMed ID: 21620108
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma.
Rich N; Tanriover B; Singal AG; Marrero JA
Transplantation; 2017 Jan; 101(1):e12-e19. PubMed ID: 28009759
[TBL] [Abstract][Full Text] [Related]
18. High model for end-stage liver disease score as a predictor of survival during long-term follow-up after liver transplantation.
Suzuki H; Bartlett AS; Muiesan P; Jassem W; Rela M; Heaton N
Transplant Proc; 2012 Mar; 44(2):384-8. PubMed ID: 22410023
[TBL] [Abstract][Full Text] [Related]
19. Living donor liver transplantation for hepatocellular carcinoma.
Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
[TBL] [Abstract][Full Text] [Related]
20. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts.
Chan SC; Sharr WW; Chok KS; Chan AC; Lo CM
Transplantation; 2013 Dec; 96(11):995-9. PubMed ID: 23924774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
